Patents for A61P 35 - Antineoplastic agents (221,099)
04/2002
04/04/2002WO2002004636A8 NOVEL α-CATENIN EXPRESSED IN HEART AND TESTIS
04/04/2002WO2002003961B1 Microspheres and adjuvants for dna vaccine delivery
04/04/2002WO2002000662B1 Improvements in and relating to chromophores
04/04/2002WO2002000167A3 Modified forms of pharmacologically active agents and uses therefor
04/04/2002WO2001097837A8 Solubilised protein vaccines
04/04/2002WO2001097795A3 Systems and methods for treating a mucosal surface
04/04/2002WO2001094347A8 Tetracyclic diketopiperazine compounds as pdev inhibitors
04/04/2002WO2001091735A3 Use of aloe-emodin in the treatment of neuroectodermal tumors
04/04/2002WO2001090306A3 Compositions and methods for modulating tumor specific expression
04/04/2002WO2001089577A3 Conjugates of aminodrugs comprising an oxime bond
04/04/2002WO2001089449A3 Phospholipase d effectors for therapy and screening
04/04/2002WO2001088106A3 Novel deoxyribonucleside kinase enzyme multi-substrate variants
04/04/2002WO2001085980A3 Enzymatic assays for screening anti-cancer agents
04/04/2002WO2001085784A3 POLYNUCLEOTIDES ENCODING FOR POLYMORPHIC ISOFORMS OF THE PTHrP PROTEIN, THE ENCODED PROTEINS AND THEIR THERAPEUTIC APPLICATIONS THEREOF
04/04/2002WO2001085209A3 Treating t-cell mediated diseases by modulating dr6 activity
04/04/2002WO2001085142A8 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
04/04/2002WO2001083689A3 PEPTIDES FROM FRAMESHIFT MUTATED DNA POLYMERASE δ GENE
04/04/2002WO2001081332A3 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
04/04/2002WO2001077294A3 Hpv-specific short-mers
04/04/2002WO2001076622A3 Immunogenic peptides derived from prostate-specific antigen (psa) and uses thereof
04/04/2002WO2001073034A3 Beta-like glycoprotein hormone polypeptide and heterodimer
04/04/2002WO2001073033A3 Anti-angiogenic and anti-tumor properties of matin and other laminin domains
04/04/2002WO2001072829A3 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
04/04/2002WO2001072781A3 Human genes and expression products
04/04/2002WO2001071022A3 Lpa receptor agonists and antagonists and methods of use
04/04/2002WO2001068837A3 Antisense oligonucleotides of the human chk1 gene and uses thereof
04/04/2002WO2001066741A3 Kcnb: a novel potassium channel protein
04/04/2002WO2001066566A3 Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids
04/04/2002WO2001064896A3 Human enzyme molecules
04/04/2002WO2001062799A3 Method for inhibiting angiogenesis using molecules that enhance plasmin activity
04/04/2002WO2001062778A3 Tumour-specific animal proteins
04/04/2002WO2001055178A9 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
04/04/2002WO2001050848A3 Clonal propagation of primate offspring by embryo splitting
04/04/2002WO2001049715A3 Methods and compositions for inhibiting neoplastic cell growth
04/04/2002WO2001047507A3 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound
04/04/2002WO2001039720A3 Dna polymerase inhibitors, mikanolide and dihydromikanolide
04/04/2002WO2001034802A3 Compositions and methods for the therapy and diagnosis of prostate cancer
04/04/2002WO2000072021A3 Cancer associated antigens and uses therefor
04/04/2002WO2000070099A3 Differential gene expression in specific regions of the brain in neurodegenerative diseases
04/04/2002US20020040146 Useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in therapy of disease states associated with vasoconstriction
04/04/2002US20020040127 Nucleotide sequences which code tumor protein for use in diagnosis, prevention and treament of tumors
04/04/2002US20020040062 For upregulation of expression of a cell antigen without inducing shedding of said antigen from the cell
04/04/2002US20020040059 Controlling cancer by reducing its growth and improving response to therapy
04/04/2002US20020040048 (2S,4R)-4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carboxylic acid N'-isobutyl-N'-(4-methyl-benzenesulfonyl)-hydrazide, for example; inhibitors of metalloproteases, e.g. zinc proteases; vasodilators
04/04/2002US20020040030 Derivatives of 3-(pyrimidin-5- yl)- and 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro(1,8) naphthyridin-2-yl)-nonanoic acid useful for inhibiting bone resorptin, restenosis, angiogenesis, diabetic retinopathy etc
04/04/2002US20020040029 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
04/04/2002US20020040022 Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection
04/04/2002US20020040011 Naphthoquinone compositions and uses thereof
04/04/2002US20020040003 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus
04/04/2002US20020040000 Human kcnq5 potassium channel, methods and compositions thereof
04/04/2002US20020039996 Pharmaceutical administration form for peptides, process for its preparation, and use
04/04/2002US20020039601 Cancer cell growth suppressor and cell differentiation inducer and method for manufacturing the same
04/04/2002US20020039583 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
04/04/2002US20020039582 Using antigen; oil in water emulsion
04/04/2002US20020039577 Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
04/04/2002US20020039575 Supplying polypepties
04/04/2002US20020039569 Activation; separation
04/04/2002US20020039557 Anticarcinogenic agents; immunosuppressant
04/04/2002DE10047272A1 Verfahren zur Fusion von dendritischen Zellen mit erkrankten Gewebezellen, insbesondere Tumorzellen und Medien für solche Verfahren Process for the fusion of dendritic cells with diseased tissue cells, particularly tumor cells and media for such methods
04/04/2002DE10045591A1 Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) Site-specific, antibody-mediated activation of proapoptotic cytokines - Amaize (Antibody Mediated Apoptosis Inducing cytokines)
04/04/2002DE10044792A1 Substituierte Phenylcyclohexancarbonsäureamide und ihre Verwendung Substituted Phenylcyclohexancarbonsäureamide and their use
04/04/2002CA2426666A1 Ion-strength independent sustained release pharmaceutical formulation
04/04/2002CA2424014A1 A novel human g-protein coupled receptor, hgprbmy7, expressed highly in spinal cord
04/04/2002CA2424004A1 Recombinant bcg vaccines for the prevention and treatment of cancer
04/04/2002CA2423991A1 Pumpcn compositions and uses thereof
04/04/2002CA2423970A1 Carbamic acid compounds comprising an ether linkage as hdac inhibitors
04/04/2002CA2423966A1 Peptide ligands for prostate specific antigen
04/04/2002CA2423955A1 Kini-3 motor protein and methods for its use
04/04/2002CA2423953A1 Hydrolases
04/04/2002CA2423919A1 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai
04/04/2002CA2423889A1 Methods and compositions for screening modulators of lipid kinases
04/04/2002CA2423704A1 G-protein coupled receptors
04/04/2002CA2423694A1 Transferases
04/04/2002CA2423668A1 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
04/04/2002CA2423487A1 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
04/04/2002CA2423483A1 Taxoid conjugates as antimitotic and antitumor agents
04/04/2002CA2423482A1 Fluorinated quinolones as antimitotic and antitumor agents
04/04/2002CA2423474A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents
04/04/2002CA2423464A1 Hydroxy acid integrin antagonists
04/04/2002CA2423434A1 Lactone integrin antagonists
04/04/2002CA2423424A1 Secreted proteins
04/04/2002CA2423413A1 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
04/04/2002CA2423305A1 Compounds useful in the treatment of inflammatory diseases
04/04/2002CA2423141A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
04/04/2002CA2422916A1 Compounds and methods for use thereof in the treatment of cancer or viral infections
04/04/2002CA2422056A1 17.alpha. fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds
04/04/2002CA2421851A1 Tgf-.beta. inhibitors and methods
04/04/2002CA2421209A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein junkinases
04/04/2002CA2420672A1 Antiangiogenic polypeptides and methods for inhibiting angiogenesis
04/04/2002CA2420645A1 Metal complexes for use in medical and therapeutic applications
04/04/2002CA2420577A1 Peptide-based compounds
04/04/2002CA2420045A1 Melanocortin receptor ligands
04/03/2002EP1193270A2 Pyrrolobenzodiazepines
04/03/2002EP1193268A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
04/03/2002EP1193267A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases
04/03/2002EP1193256A1 Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
04/03/2002EP1193250A1 Phenyl sulfamate derivatives
04/03/2002EP1192948A2 Use of HSV mutant in the treatment of cancer
04/03/2002EP1192450A1 High energy phototherapeutic agents
04/03/2002EP1192271A1 Antisense modulation of interleukin-5 signal transduction